Although we maintain the text relating to atezolizumab related PD-L1 testing, it must be mentioned that the United States Food and Drug Administration has suspended the accelerated approval of atezolizumab for metastatic triple negative breast cancer, and accordingly the National Cancer Collaborative Network (NCCN) guideline has removed the footnote advising testing for PD-L1 for the identification of candidates for atezolizumab therapy (83). The gene discussed is CD274; the disease is triple-negative breast carcinoma.